For children with unexplained fevers, painful mouth sores, and gut inflammation that resemble Behçet's disease (BD) but do not meet diagnostic criteria, doctors have long faced a clinical puzzle. Now, researchers have formalized a concept that may help solve it: Behçet's spectrum disorders (BSD). First introduced in 2020, the BSD framework unifies a diverse set of inflammatory conditions—from rare monogenic diseases to common recurrent canker sores—by shared immune pathways, aiding clinicians in recognizing Behçet-like inflammation earlier and prioritizing genetic testing in children whose symptoms fall outside classic patterns.
Behçet's disease is a systemic vasculitis marked by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. Moreover, a growing number of monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms yet are biologically distinct and require different therapies. This diagnostic overlap frequently leads to misdiagnosis, inappropriate treatment, and prolonged suffering. Although the BSD concept was introduced in 2020, a practical clinical framework for early recognition and genetic prioritization in children has remained elusive.
A team from Peking Union Medical College Hospital in Beijing has now published a review in the World Journal of Pediatrics (June 23, 2026) that comprehensively maps BSD. The researchers propose a tiered classification: "core BSD" for monogenic diseases that directly converge on BD-defining inflammatory pathways, and "peripheral BSD" for conditions with partial clinical overlap or indirect mechanistic connections. The goal is not to replace existing diagnostic criteria but to provide a mechanism-oriented lens for earlier recognition and genetic screening in children with Behçet-like presentations.
This systematic review establishes a two-tier BSD classification grounded in genetic and mechanistic evidence. The core BSD tier comprises monogenic diseases that directly disrupt NF‑κB or JAK‑STAT signaling—specifically HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and show strong convergence on BD-relevant inflammatory circuits. The peripheral BSD tier includes polygenic or multifactorial entities such as recurrent aphthous stomatitis, PFAPA syndrome, DADA2, and trisomy 8-associated disease, which exhibit partial clinical overlap or indirect pathway engagement. A major highlight is the identification of NF‑κB and JAK‑STAT as two central inflammatory hubs common across the spectrum, providing a rational basis for grouping these disorders. The authors also delineate exclusion criteria, distinguishing true spectrum members from phenotypic mimics like LIG4 deficiency and IKBKG (NEMO) mutations.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing targeted therapies—such as IL‑1, TNF, or JAK inhibitors—for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations. Ultimately, this framework empowers pediatricians to move towards precision medicine, offering hope for children with complex, refractory inflammatory conditions that have long defied conventional diagnosis and treatment.
